Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 12225 in total
Approved
Experimental
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a...
Approved
Matched Description: … Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability ... [A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment ... [A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development …
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Description: … Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors ... that presented a greater selectivity and potency when compared with other agents from this group. ... [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural ... [A243356, A243361] Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural ... [A243356, A243361] Tixagevimab (formerly AZD8895) is a recombinant monoclonal antibody produced in Chinese …
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug ... Rotigotine has been authorized as a treatment for RLS since August 2008. ... Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease …
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive ... [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa ... [T734] Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method …
Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. This is...
Approved
Investigational
Matched Description: … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for ... [A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates ... from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst...
Approved
Investigational
Matched Description: … [A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling ... [A227458] As a direct stimulator of sGC, vericiguat mitigates the need for a functional NO-sGC-cGMP axis ... Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic …
Peanut oil is derived from Arachis hypogaea which can be found in South America, Mexico, and Centro America. The kernels are consumed roasted but a large percentage is used for the production of vegetable oil. The peanut oil represents about 45-52% of the kernel content and it is mainly formed...
Approved
Matched Description: … The kernels are consumed roasted but a large percentage is used for the production of vegetable oil. …
Wormwood is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Approved
Experimental
Matched Description: … Wormwood is a plant/plant extract used in some OTC (over-the-counter) products. …
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Approved
Investigational
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Aspergillus oryzae allergenic extract is used in allergenic testing.
Approved
Protokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States.
Approved
Vet approved
Matched Description: … Protokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States …
Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is not available in North America . It has been found to have carcinogenic potential in mammalian cells as...
Approved
Matched Description: … Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved ... Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study …
Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Approved
Investigational
Matched Description: … Famciclovir is a prodrug of penciclovir with higher oral bioavailability. ... Famciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections …
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal ... Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Approved
Matched Description: … A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant ... Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen …
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. ... first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and DB09301 , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting...
Approved
Withdrawn
Matched Description: … of a mixture of glycosaminoglycans [A32565]. ... Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting ... Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor …
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Description: … [L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with ... Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been …
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment ... found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a ... A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Description: … mechanism of action has not been described in the literature, though it positively modulates GABAA< …
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage...
Approved
Investigational
Matched Description: … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic ... Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. ... [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients …
Displaying drugs 751 - 775 of 12225 in total